The use and potential abuse of anticholinergic antiparkinson drugs in Norway: A pharmacoepidemiological study

British Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2009, Pages 228-233

  Gjerden, Pål ^a   Bramness, Jørgen G ^b   Slørdal, Lars ^c  

^a TELEMARK HOSPITAL   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

Adverse effects; Anticholinergic agents; Antiparkinson agents; Antipsychotic agents; Drug abuse

Indexed keywords

ALPRAZOLAM; ANTIPARKINSON AGENT; BIPERIDEN; BROMAZEPAM; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOBAZAM; DIAZEPAM; LORAZEPAM; NEUROLEPTIC AGENT; ORPHENADRINE; OXAZEPAM;

ADULT; AGED; ARTICLE; DRUG ABUSE; DRUG INDICATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NORWAY; PARKINSON DISEASE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BIPERIDEN; CHOLINERGIC ANTAGONISTS; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NORWAY; ORPHENADRINE; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 61349156022     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03342.x     Document Type: Article

References (26)

1. Dillon C, Paulose-Ram R, Hirsch R, Gu Q. Skeletal muscle relaxant use in the United States: data from the Third National Health and Nutrition Examination Survey (NHANES 3). Spine 2004 29 : 892 6.
2. Hunskaar S, Donnell D. Clinical and pharmacological review of the efficacy of orphenadrine and its combinations with paracetamol in painful conditions. J Int Med Res 1991 19 : 71 87.
3. Schaffler K, Reitmeir P, Gschanes A, Eggenreich U. Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse) with its single active ingredients diclofenac and orphenadrine: a placebo-controlled study using laser-induced somatosensory-evoked potentials from capsaicin-induced hyperalgesic human skin. Drugs R&D 2005 6 : 189 99.
4. Buhrich N, Weller A, Kevans P. Misuse of anticholinergic drugs by people with serious mental illness. Psychiatr Serv 2000 51 : 928 9.
5. Brocks DR. Anticholinergic drugs used in Parkinson's disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharmaceut Sci 1999 2 : 39 46.
6. Labout JJM, Thijssen CT, Keijser GGJ, Hespe W. Differences between single and multiple dose pharmacokinetics of orphenadrine hydrochloride in man. Eur J Clin Pharmacol 1982 21 : 343 50.
7. Dollery C, ed. Therapeutic Drugs, 2nd edn. Edinburgh : Churchill Livingstone, 1999.
8. Gjerden P, Slørdal L. The clinical pharmacology of anticholinergic antiparkinsonian drugs: a review with emphasis on acute toxicity. Tidsskr Nor Laegeforen 1998 118 : 53 5.
9. Gjerden P, Engelstad KS, Pettersen G, Slørdal L. Fatalities caused by anticholinergic antiparkinsonian drugs: a retrospective study of a series of Norwegian cases. Tidsskr Nor Laegeforen 1998 118 : 42 4.
10. Buckley N, McManus P. Fatal toxicity of drugs used in the treatment of psychotic illnesses. Br J Psychiatry 1998 172 : 461 4.
11. Lau HS, Riezebos J, Abas V, Porsius AJ, DeBoer A. A nation-wide study on the practice of euthanasia and physician-assisted suicide in community and hospital pharmacies in the Netherlands. Pharm World Sci 2000 22 : 3 9.
12. Strom BL, ed. Pharmacoepidemiology, 3rd edn, Hoboken NJ : John Wiley & Sons, 2000.
13. Arfken CL, Cicero TJ. Postmarketing surveillance for drug abuse. Drug Alcohol Depend 2003 79 : S97 105.
14. Gaist D, Andersen M, Aarup A-L, Hallas J, Gram LG. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997 43 : 429 33.
15. Hallas J. Drug utilization statistics for individual-level pharmacy dispensing data. Pharmacoepidemiol Drug Saf 2005 14 : 455 63.
16. Bramness JG, Furu K, Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study. Br J Clin Pharmacol 2007 64 : 210 8.
17. Furu K, Strøm H, Rønning M, Skurtveit S, Engedal A, Tverdal A. The Norwegian Prescription Database (NorPD): new register for pharmacoepidemiological research covering a whole nation. Pharmacoepidemiol Drug Saf 2005 14 (Suppl. 2 S48.
18. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo : WHO, 2005.
19. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TRE. Benzodiazepines for neuroleptic-induced acute akathisia (Review). The Cochrane Database of Systematic Reviews 1999, Issue 4. Art. No.: CD001950. DOI: 10.1002/14651858. CD001950.
20. Fowler IL, Carr VJ, Carter NT, Lewin TJ. Patterns of current and lifetime substance use in schizophrenia. Schizophr Bull 1998 24 : 443 55.
21. Cantor-Graae E, Nordstrøm LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001 48 : 69 82.
22. Winklbaur B, Ebner N, Sachs G, Thau K, Fischer G. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci 2006 8 : 37 43.
23. Saran AS. Use or abuse of antiparkinsonian drugs by psychiatric patients. J Clin Psychiatry 1986 47 : 130 2.
24. Crawshaw JA, Mullen PE. A study of benzhexol abuse. Br J Psychiatry 1984 145 : 300 3.
25. Marken PA, Stoner SC, Bunker MT. Anticholinergic drug abuse and misuse. Epidemiology and therapeutic implications. CNS Drugs 1996 5 : 190 9.
26. Zemishlany Z, Aizenberg D, Weiner Z, Weizman A. Ttrihexyphenidyl (Artane) abuse in schizophrenic patients. Int Clin Psychopharmacol 1996 11 : 199 202.